Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949186 | PMC |
| http://dx.doi.org/10.2188/jea.JE20190251 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Temporal trends and patterns for early- and late-onset adult liver cancer incidence vary by race/ethnicity, subsite, and histologic type in the United States from 2000 to 2019.
Cancer Causes Control
January 2025
Epidemiology Department, College of Public Health, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Purpose: To examine incidence trends and patterns for early- and late-onset liver cancer.
Methods: Liver and intrahepatic bile duct (IBD) cancers diagnosed between 2000 and 2019 were acquired from 22 SEER registries. Variables included early-onset (20-49) vs.
Questionnaire on the surgical indications for intrahepatic cholangiocarcinoma administered to Japanese board-certified expert hepatobiliary and pancreatic surgeons and instructors.
J Hepatobiliary Pancreat Sci
January 2025
Department of Gastroenterological Surgery, Hiroshima University Hospital, Hiroshima, Japan.
Background: Treatment of intrahepatic cholangiocarcinoma (ICC) remains challenging owing to the lack of clear guidelines on surgical resection. The 2021 ICC guidelines have not fully resolved the ongoing debate between surgical and nonsurgical treatment options. This study aimed to identify trends and issues in ICC treatment strategies in the clinical field by surveying the attitudes of hepatobiliary and pancreatic (HBP) surgeons.
View Article and Find Full Text PDFAKR1B10 and digestive tumors development: a review.
Front Immunol
December 2024
Medical School, Hunan University of Chinese Medicine, Changsha, Hunan, China.
Aldo-keto reductase family 1 member B10 (AKR1B10) is a member of the AKR1B subfamily. It is mainly found in cytoplasm, and it is typically expressed in the stomach and intestines. Given that its expression is low or absent in other tissues, AKR1B10 is a potential diagnostic and therapeutic biomarker for various digestive system diseases.
View Article and Find Full Text PDFInternational trends in biliary tract cancer-related mortality, 2000-2022: An observational study of the World Health Organization mortality database.
Hepatology
December 2024
Department of Health Data Science, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Background Aims: Biliary tract cancers (BTCs), including intrahepatic cholangiocarcinoma (iCCA), extrahepatic cholangiocarcinoma (eCCA), gallbladder cancer (GBC), and ampullary cancer, exhibit poor prognosis. This study examined temporal trends in mortality due to BTCs and their major subtypes at international, regional, and national levels.
Approach Results: This observational study used the World Health Organization mortality database.
Rising Mortality of Intrahepatic Cholangiocarcinoma Among Older Adults in the United States: An Analysis of Demographic and Regional Trends.
Liver Int
January 2025
Department of Medicine, Arnot Ogden Medical Center, Elmira, New York, USA.
Introduction: Intrahepatic cholangiocarcinoma (ICC) is the second most frequent primary liver malignancy after hepatocellular carcinoma. Contemporary mortality trends due to ICC are largely unknown. We aim to examine the temporal trends of ICC-related deaths among older adults in the United States from 1999 to 2022.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!